Philippe Charron
Overview
Explore the profile of Philippe Charron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
10965
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gribissa S, Kueffer T, Knecht S, Waintraub X, Badenco N, Charron P, et al.
JACC Clin Electrophysiol
. 2025 Mar;
PMID: 40088215
Background: Pulsed-field ablation (PFA) may be beneficial for the treatment of atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM). Objectives: The goal of this study was to compare the...
2.
Laredo M, Charpentier E, Soulez S, Nguyen V, Martino A, Calo L, et al.
J Cardiovasc Magn Reson
. 2025 Feb;
:101867.
PMID: 40021092
Background: Arrhythmogenic cardiomyopathy (ACM) related to Desmoplakin (DSP) mutations is a distinct condition associated with particularly severe outcomes, more frequent left ventricular (LV) involvement including fibrosis, dysfunction and inflammatory episodes....
3.
Souilla L, Werner O, Huguet H, Gavotto A, Vincenti M, Pasquie J, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2461795.
PMID: 39998828
Importance: Historical restrictions on children with inherited cardiac arrhythmia or cardiomyopathy have been implemented to mitigate the potential risk of sudden death, but these limitations can be detrimental to overall...
4.
Mizia-Stec K, Gimeno J, Charron P, Elliott P, Kaski J, Maggioni A, et al.
Open Heart
. 2025 Feb;
12(1).
PMID: 39961701
Background: Hypertrophic cardiomyopathy (HCM) is commonly associated with atrial fibrillation (AF), but its impact on outcomes in real-world practice is uncertain. The aim of the study was to evaluate the...
5.
Gaudillat L, Patay L, Sawka C, Baurand A, Nambot S, Level C, et al.
Eur J Med Genet
. 2025 Feb;
74:104999.
PMID: 39933637
Scientific advances in genomics are transforming healthcare and prevention. However, they also increase situations of uncertainty, which in turn increase vulnerability not only for patients and their families but also...
6.
Charron P, Zema C, Cotte F, Herquelot E, Krause T, Dayde F, et al.
Front Cardiovasc Med
. 2025 Feb;
11:1458410.
PMID: 39911844
Background: Hypertrophic cardiomyopathy (HCM) can be genetic and occurs as obstructive and non-obstructive 21 subtypes. Little is known about the clinical burden of the obstructive subtype of HCM at a...
7.
Massier M, de Groote P, Donal E, Magnin-Poull I, Coubes C, Le Guillou Horn X, et al.
Clin Genet
. 2025 Jan;
107(4):425-433.
PMID: 39844436
Titin truncating variants (TTNtv) are the main genetic cause of dilated cardiomyopathies (DCMs). The phenotype and prognosis of probands have been evaluated in several large cohorts. However, few data are...
8.
Hermida A, Ader F, Millat G, Jedraszak G, Vogel L, Garcon L, et al.
Circ Heart Fail
. 2025 Jan;
e012492.
PMID: 39823286
No abstract available.
9.
Charron P, Proukhnitzky J
Heart
. 2025 Jan;
PMID: 39798963
Advances in molecular genetics during the past decades led to seminal discoveries in the genetic basis of cardiovascular diseases, resulting in a new understanding of their pathogenesis, determinants of natural...
10.
Jurgens S, Ramo J, Kramarenko D, Wijdeveld L, Haas J, Chaffin M, et al.
Nat Genet
. 2024 Dec;
56(12):2843.
PMID: 39633063
No abstract available.